Key clinical point: A post hoc analysis suggests lenalidomide maintenance therapy does not reduce health-related quality of life (HRQoL) in patients with diffuse large B-cell lymphoma (DLBCL).

Major finding: Among patients who received lenalidomide, there were no significant changes observed in 3 major HRQoL domains: fatigue, physical functioning, and global health status).

Study details: A subpopulation analysis of data for 457 patients from the phase 3 REMARC trial.

Disclosures: The study was funded by Celgene. The authors reported financial affiliations with Celgene and other companies.